Drugs / Basal Insulin Peglispro
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03025009 Comparator | Mar 2017 → Apr 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Basal Insulin Peglispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03025009 ↗ |
| Route | Subcutaneous | “Basal insulin peglispro administered as a SC injection in one of three study periods.” NCT03025009 ↗ |